Living with blood cancer often means lifelong treatment, frequent hospital visits, and managing challenging side effects. But what if there are more ways to improve both care and quality of life? 🔗 Read more: bit.ly/43z2Brb

We’re proud to join industry leaders and key policymakers at the #SilverEconomyForum in Manchester to discuss how we can foster trust in science to get ahead of disease and build more resilient societies. Watch this video to learn more about our approach to unlocking the power of prevention 👇

#News for #investors and #media: At #TLM25 we’ll share new data from our advancing hepatology pipeline - with 21 abstracts covering CHB, MASH, ALD and PBC. We remain committed to addressing the global burden of liver disease. Learn more: gsk.to/3WJNqIa#News

Join us at the American Society of Nephrology congress this week, as we partner with nephrology leaders to talk about the importance of protecting kidney function and supporting long-term health outcomes for people living with lupus.

"One person doesn’t make a difference. We all come together, and we make it happen.” From facing cancer to co-founding the Multiple Myeloma Research Foundation, Kathy Giusti has made a huge difference to the lives of so many living with cancer. 🎥 Watch more: gsk.to/4nfiSJ7

Today we announce our Q3 2025 results, with another quarter of strong performance and upgraded guidance for 2025. Hear more from our CEO Emma Walmsley ⤵️ More information for media and investors: gsk.com $GSK #Q3Results

#News for #investors and #media: Today we announced an agreement with Empirico to add to our pipeline in COPD and potentially other inflammatory respiratory diseases. Find out more: gsk.to/4oF5Vt6

#News for #Investors and #Media: Today we announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to an investigational antibody-drug conjugate in our oncology pipeline. Learn more here: gsk.to/4hwnHfz

#News for #investors and #media: Today we announced an agreement with Syndivia to add to our growing oncology pipeline in prostate cancer. Find out more: gsk.to/4nrTYFX

#News for #Investors and #Media The US Food and Drug Administration (FDA) has approved our therapy to treat an incurable and challenging blood cancer. For more information, visit: www.gsk.com#News

“Our patients - including families just like mine - are relying on us. We won't let them down.” In this article, Hesham Abdullah shares his family's story and how his team are working tirelessly to realise a future where people don't just survive cancer but thrive long after. 🔗bit.ly/4o9ASpq

We’re at #IDWeek2025 because infectious diseases remain one of the greatest public health challenges, responsible for one in six deaths worldwide. Many are still overlooked, and rising resistance is making treatment options less effective. ➡️ Want to learn more? www.gsk.com/en-gb/innova...

#News for #investors and #media: We’ve just announced data from our pivotal phase III clinical programme for a metered dose inhaler (MDI): gsk.to/4nkQipr

Together with ViiV Healthcare, we’re investing a total of £6m in the Global Fund, to help them fund locally led programmes that are tackling the high burden of HIV, tuberculosis and malaria in lower income countries.

#News for #Investors and #Media: The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for a new prefilled syringe presentation of one of our vaccines. Learn more: gsk.to/47egZpR

#News for #Media and #Investors: Today, with Spero, we are sharing an update on the Phase III trial results of one of our investigational oral anti-infectives, presented during #IDWeek2025 in Atlanta. Learn more: gsk.to/47h8tGN#News

“It’s hard to explain the pain of a UTI to people who’ve never had one.” 🔗 Read LeAnn’s story and why she thinks personalised care is so important: gsk.to/4hkD8aO #IDWeek2025

Modern medicine has revolutionised the way we live but the challenges to our health are evolving. Find out why preventing disease is the best investment not just for people but also for the world’s health systems, societies and economies 👇 #IDWeek2025

Understanding the challenges faced by those living with gynaecologic cancers is key to driving change. Visit us at #ESMO25 to learn more about our Your Cancer Is Our Challenge survey and how we’re working to amplify patient voices and improve care. 🔗 Learn more: bit.ly/4h9h2YB

Globally, one in five people will be diagnosed with cancer in their lifetime. We’re working to change outcomes for patients facing that reality. By advancing innovative oncology research, we’re aiming to redefine what’s possible in cancer care. ➡️ Find us at #ESMO25 this week to learn more.

Evolving health threats demand focus on prevention. At the #WorldHealthSummit, we discussed the need to work together to help preventative interventions reach people who need them. Prioritising prevention can transform lives, protect global health & boost economies: gsk.to/3W4Etc2#WorldHealthSummit

Great discussion with @statnews.com and @matthewherper.bsky.social at the 2025 #StatSummit. Emma highlighted our strong investment in the US, focus on preventative healthcare, and how AI is reshaping our business.

At the @worldhealthsummit.bsky.social, we came together with @savechildrenuk.bsky.social to explore the role of partnerships in tackling evolving global health challenges. Collaboration is key for innovation and access to healthcare. Learn more in our impact report: gsk.to/474wYXt

#News for #Investors and #Media: Data presented at #EACS2025 by our specialist HIV company, ViiV Healthcare, offer a deeper understanding of therapy options & could help individuals & their healthcare providers make more fully informed choices about their HIV care. Find out more: gsk.to/4qacmpF

Inspiring to see our CEO Emma Walmsley at the Fortune Most Powerful Women Summit in D.C. She shared her vision for the future of healthcare, touching on cancer treatment discoveries & AI's role, and reflected on her nine years leading GSK's transformation. #FortuneMPW

Technology transfers are one of the tools available to support access to new innovations in vaccines and medicines, including antibiotics. At the @worldhealthsummit.bsky.social, we co-hosted a panel discussion to highlight the opportunities that tech transfer brings, but also the complexities.

We believe in the power of vaccines to protect billions.

We believe HIV has a past but not a future.

We believe prevention is the best medicine.

We believe that getting ahead of disease requires understanding its root cause.

We believe outsmarting cancer demands focus.

We believe beating respiratory disease demands breathtaking innovation.

We're here to share our journey of uniting science, tech, and talent to help get ahead of disease, together. Expect updates on our ongoing research, developments in vaccines and medicines, and how we're making a positive impact on global health. We're looking forward to connecting with you.